四硫代钼酸胆碱

四硫代钼酸胆碱
臨床資料
商品名（英语：Drug nomenclature）	Decuprate
其他名稱	四硫代钼酸双胆碱; 双胆碱四硫代钼酸盐; ATN-224、WTX101
ATC碼	未分配;
法律規範狀態
法律規範	Investigational;
识别信息
CAS号	649749-10-0
PubChem CID	18442052;
DrugBank	DB05088;
ChemSpider	19906891;
UNII	91U3TGV99T;
化学信息
化学式	C10H28MoN2O2S4
摩尔质量	432.542 g/mol
3D模型（JSmol（英语：JSmol））	交互式图像;
	SMILES OCC[N+](C)(C)C.[S-][Mo]([S-])(=S)=S.C[N+](C)(C)CCO;
	InChI InChI=1S/2C5H14NO.Mo.4S/c21-6(2,3)4-5-7;;;;;/h27H,4-5H2,1-3H3;;;;;/q2+1;;;;2-1; Key:NEYVHGQOGHJAAD-UHFFFAOYSA-N;

四硫代钼酸胆碱（又称胆碱四硫代钼酸盐，商品名为Decuprate），是胆碱所形成的硫代钼酸盐（TTM, MoS₄²⁻）。作为威尔逊氏病的治疗方法，这是一种身体不能调节铜的罕见且潜在的致命疾病。威尔逊病是一种常染色体隐性遗传性疾病，有严重的肝、神经或精神症状的表现。若未经诊断和未经治疗，该疾病可能致命。据估计，全世界每3万人中约有1人患有威尔逊氏病，相当于欧盟约有1万5千人而美国约有1万1千人。^[1]

已经在患有各种癌症的患者的临床试验中评估了四硫代钼酸胆碱，^[2]^[3]^[4]并在美国和欧盟成为了孤儿药（即罕见药），作为威尔逊氏病的潜在治疗方法。^[5]^[6]

四硫代钼酸胆碱是威尔逊治疗学公司的代号为WTX101的威尔逊氏病临床开发中的去铜疗法用药，该公司由HealthCap于2012年成立。

参考文献

^ Ala, A; Walker, A. P.; Ashkan, K; Dooley, J. S.; Schilsky, M. L. Wilson's disease. The Lancet. 2007, 369 (9559): 397–408. PMID 17276780. doi:10.1016/S0140-6736(07)60196-2.
^ Berenson JR, Boccia RV, Bashey A, Levine AM, Koc ON, Callahan JA, Mazar AP, Reich SD. Phase I Study of the [Cu, Zn] Superoxide Dismutase (SOD1) Inhibitor ATN-224 (Bis-Choline Tetrathiomolybdate) in Patients with Advanced Hematologic Malignancies Presentation at the Amer Soc Hematol 2006 Annual Meeting. Blood. 2006, 108. Abstract 2593.
^ Lin, J; Zahurak, M; Beer, T. M.; Ryan, C. J.; Wilding, G; Mathew, P; Morris, M; Callahan, J. A.; Gordon, G; Reich, S. D.; Carducci, M. A.; Antonarakis, E. S. A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer. Urologic Oncology: Seminars and Original Investigations. 2013, 31 (5): 581–8. PMC 3227793  . PMID 21816640. doi:10.1016/j.urolonc.2011.04.009.
^ Lowndes, S. A.; Adams, A; Timms, A; Fisher, N; Smythe, J; Watt, S. M.; Joel, S; Donate, F; Hayward, C; Reich, S; Middleton, M; Mazar, A; Harris, A. L. Phase I study of copper-binding agent ATN-224 in patients with advanced solid tumors. Clinical Cancer Research. 2008, 14 (22): 7526–34. PMID 19010871. doi:10.1158/1078-0432.CCR-08-0315.
^ Public summary of opinion on orphan designation: Choline tetrathiomolybdate for the treatment of Wilson's disease （页面存档备份，存于互联网档案馆）, EMA/COMP/795268/2012, ATN-224, 18 February 2013.
^ Orphan Drug Designations and Approvals: choline tetrathiomolybdate （页面存档备份，存于互联网档案馆）, U.S. Food and Drug Administration, 25 August 2011

[1] Ala, A; Walker, A. P.; Ashkan, K; Dooley, J. S.; Schilsky, M. L. Wilson's disease. The Lancet. 2007, 369 (9559): 397–408. PMID 17276780. doi:10.1016/S0140-6736(07)60196-2.

[Berenson-2] Berenson JR, Boccia RV, Bashey A, Levine AM, Koc ON, Callahan JA, Mazar AP, Reich SD. Phase I Study of the [Cu, Zn] Superoxide Dismutase (SOD1) Inhibitor ATN-224 (Bis-Choline Tetrathiomolybdate) in Patients with Advanced Hematologic Malignancies Presentation at the Amer Soc Hematol 2006 Annual Meeting. Blood. 2006, 108. Abstract 2593.

[Lin-3] Lin, J; Zahurak, M; Beer, T. M.; Ryan, C. J.; Wilding, G; Mathew, P; Morris, M; Callahan, J. A.; Gordon, G; Reich, S. D.; Carducci, M. A.; Antonarakis, E. S. A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer. Urologic Oncology: Seminars and Original Investigations. 2013, 31 (5): 581–8. PMC 3227793  . PMID 21816640. doi:10.1016/j.urolonc.2011.04.009.

[Lowndes-4] Lowndes, S. A.; Adams, A; Timms, A; Fisher, N; Smythe, J; Watt, S. M.; Joel, S; Donate, F; Hayward, C; Reich, S; Middleton, M; Mazar, A; Harris, A. L. Phase I study of copper-binding agent ATN-224 in patients with advanced solid tumors. Clinical Cancer Research. 2008, 14 (22): 7526–34. PMID 19010871. doi:10.1158/1078-0432.CCR-08-0315.

[5] Public summary of opinion on orphan designation: Choline tetrathiomolybdate for the treatment of Wilson's disease （页面存档备份，存于互联网档案馆）, EMA/COMP/795268/2012, ATN-224, 18 February 2013.

[6] Orphan Drug Designations and Approvals: choline tetrathiomolybdate （页面存档备份，存于互联网档案馆）, U.S. Food and Drug Administration, 25 August 2011

[1]

[2]

[3]

[4]

[5]

[6]